EW250117C105000
- 0.04
- -0.01-20.00%
Edwards Lifesciences Newsroom
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $85
Deutsche Bank Sticks to Its Buy Rating for Edwards Lifesciences (EW)
Baird Adjusts Edwards Lifesciences Price Target to $70 From $68, Maintains Neutral Rating
Morgan Stanley Downgrades Edwards Lifesciences(EW.US) to Sell Rating, Cuts Target Price to $46
Edwards Lifesciences: Competitive Pressures and Valuation Concerns Lead to Sell Rating
Bernstein Downgrades Edwards Lifesciences(EW.US) to Sell Rating, Announces Target Price $73
BofA Securities Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $90
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Price Target Is $90
Edwards Lifesciences Analyst Ratings
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $83
Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $78
Edwards Lifesciences (EW) Receives a Hold From Truist Financial
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $75 to $90
Oppenheimer Remains a Buy on Edwards Lifesciences (EW)
Edwards Lifesciences (EW) Receives a Buy From RBC Capital
Bank of America Securities Keeps Their Hold Rating on Edwards Lifesciences (EW)
Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $90
Hold Rating for Edwards Lifesciences: Balancing Risks and Opportunities Amidst Market Variability
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)
UBS Adjusts Price Target on Edwards Lifesciences to $78 From $75, Keeps Neutral Rating